**Understanding factors influencing vaccination acceptance during pregnancy globally**: **A literature review**

Rose J Wilsona\*

[rose.wilson@lshtm.ac.uk](mailto:rose.wilson@lshtm.ac.uk)

Pauline Patersona

[Pauline.paterson@lshtm.ac.uk](mailto:Pauline.paterson@lshtm.ac.uk)

Caitlin Jarretta

[Caitlin.jarrett@lshtm.ac.uk](mailto:Caitlin.jarrett@lshtm.ac.uk)

Heidi J Larsona,b

[Heidi.larson@lshtm.ac.uk](mailto:Heidi.larson@lshtm.ac.uk)

a London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom

b Department of Global Health, University of Washington, Seattle, USA

\* Corresponding author, Tel: 020 7299 4740

**Abstract**

Maternal vaccination has been evaluated and found to be extremely effective at preventing illness in pregnant women and new-borns, however, uptake of such programmes has been low in some areas.

To analyse factors contributing to uptake of vaccines globally, a systematic review on vaccine hesitancy was carried out by The Vaccine Confidence Project in 2012. In order to further analyse factors contributing to uptake of maternal immunisation, a further search within the broader systematic review was conducted using the terms 'Prenan\*' or 'Matern\*'. Forty-two articles were identified. Pregnancy-related articles were further screened to identify those focused on concerns, trust and access issues regarding maternal vaccination reported by pregnant women and healthcare workers. Thirty-five relevant articles were included which were then searched using the snowballing technique to identify additional relevant references cited in these articles. A search alert was also conducted from February to April 2015 in PubMed to ensure that no new relevant articles were missed. A total of 155 relevant articles were included.

Most of the literature which was identified on hesitancy surrounding vaccination during pregnancy reports on determinants of influenza vaccine uptake in North America. Research conducted in low-income countries focused primarily on tetanus vaccine acceptance. The main barriers cited were related to vaccine safety, low knowledge about the vaccines, their efficacy, availability and/or the diseases they prevent, and the absence of recommendations from healthcare workers. From the point of view of healthcare workers, barriers included inadequate training, inadequate reimbursement and increased workload. Twenty-seven out of 46 (59%) articles mentioning ethnicity reported lower rates of coverage among ethnic minorities.

Barriers to vaccination in pregnancy are complex and vary depending on context and population. There are wide gaps in knowledge regarding the attitudes of healthcare workers and how ethnicity and gender dynamics influence a pregnant woman’s decision to vaccinate.

**Keywords:** Vaccine hesitancy,maternal immunisation, maternal vaccination, pregnancy, racial/ethnic minorities.

**Introduction**

Over the past two decades, tremendous progress has been made in halving worldwide maternal and child deaths, supported by the drive to meet Millennium Development Goals (MDGs) by 2015. One of the targets of UN The Sustainable Development Goals (SDGs) aims to continue this momentum by reducing the global maternal mortality ratio to less than 70 per 100,000 live births ([2](#_ENREF_2)).

Maternal vaccination programmes have been evaluated and found to be extremely effective at preventing illness in pregnant women and new-borns ([3](#_ENREF_3), [4](#_ENREF_4)).The pertussis vaccine is given as part of a combined product: diphtheria/tetanus/acellular pertussis/inactivated polio vaccine (dTaP/ IPV) ([5](#_ENREF_5)). Influenza and dTaP/IPV vaccinations during pregnancy are now offered in many countries, including Australia, Belgium, Canada, China, France, Germany, India, Mexico, the Netherlands, Poland, Spain, Slovenia, Switzerland, Turkey, the UK and the USA. The Monovalent maternal tetanus vaccination is implemented as part of the routine immunization program in most developing countries. And, Group B Streptococcus (GBS) vaccines are currently being developed for use in pregnancy.

Pertussis and influenza are preventable diseases with potentially severe consequences for new-born infants and in the case of influenza, for pregnant women. Infants under the age of six months are vulnerable to transmission of pertussis and influenza infection from others, especially their mothers. The most common clinical syndromes due to pertussis, requiring intensive care admission in infants, are apnoea, pneumonia and seizures. Most deaths are associated with the presence of pneumonia ([6](#_ENREF_6)).

Globally, there remain approximately 600,000 infection-related neonatal deaths per year ([7](#_ENREF_7)) and mortality reduction in new-born infants under one year of age has been gradual, especially in the highest burden countries in Africa ([8](#_ENREF_8)), declining on average three percent per year since 1990 ([9](#_ENREF_9)). The relative proportion of new-born deaths now accounts for about 44% of the total under-five mortality and new-borns are projected to make up 55% of all under-five mortality by 2035 ([10](#_ENREF_10)). If the present rate of decline continues, it will be over a century before an African new-born baby has the same survival probability as one born in Europe or North America in 2013—three times longer than this decline took in industrialised countries before neonatal intensive care began ([8](#_ENREF_8)).

Childhood deaths associated with influenza are most frequent in infants under the age of six months; Influenza can also cause bacterial pneumonia and otitis media. Maternal influenza infection has been associated with an increased risk of hospitalisation relative to non-pregnant women of the same age: in an analysis of acute respiratory illness visits within a managed-care organization, non-pregnant women had ten excess visits per 1,000 compared with 23.7 excess visits per 1,000 among pregnant women ([11](#_ENREF_11)). Recent evidence also argues that there could be a direct effect of influenza infection on the foetal brain; Aronsson (2001) ([12](#_ENREF_12)) reported that mice that were prenatally infected with human influenza had influenza viral ribonucleic acid (RNA) in the brain.

Influenza and pertussis vaccine uptake in pregnancy are around 40% ([13](#_ENREF_13)) and 62.3% ([14](#_ENREF_14)) respectively in England. In comparison, vaccine uptake in pregnancy is much lower in other countries, such as Australia ([15](#_ENREF_15)), China ([16](#_ENREF_16)), Nigeria ([17](#_ENREF_17)) and the USA ([18](#_ENREF_18)). These lower uptake rates have been reported as being due to challenges such as lack of knowledge on the part of health care workers (HCW) and pregnant women related to the safety and efficacy of vaccines provided during pregnancy ([19](#_ENREF_19)), complex delivery arrangements involving different HCW, challenges in data collection and reporting ([20](#_ENREF_20)) and because the vaccines were newly introduced. Pregnant women and HCW also report feeling confused by mixed messages regarding vaccination and medication in pregnancy.

Maternal and neonatal tetanus (MNT) are among the most common lethal consequences of unclean deliveries and umbilical cord care practices in many countries ([21](#_ENREF_21)). However, on the basis of cause-of-death trends (2000–2012), tetanus had the largest relative decrease, of more than two-thirds from 1.3 deaths (per 1000 live births) to 0.4. This decrease is associated with substantial increases in tetanus toxoid vaccination ([22](#_ENREF_22)) and may also relate to improved cleanliness, cord care practices and education ([23](#_ENREF_23)).  High vaccination uptake however, must be sustained as neonatal tetanus is an acute disease presenting initially with loss of ability to suck, followed by generalized rigidity and painful muscle spasms as the disease progresses. Most (90%) cases of neonatal tetanus develop symptoms during the first 3–14 days of life with the majority presenting at 6–8 days. Mortality is very high: in the absence of medical treatment, case fatality approaches 100% ([24](#_ENREF_24)).

In terms of new vaccines in the pipeline, preclinical and human phase I studies of Group B Streptococcus (GBS) vaccine have been completed demonstrating the safety and immunogenicity of the vaccine. Phase III vaccine trials are still needed to determine the clinical efficacy of maternal GBS vaccination ([25](#_ENREF_25)) but acceptability of this vaccine would be extremely important as GBS is the leading cause of meningitis in the early new-born period. Infants who survive GBS meningitis often [face lifelong moderate to severe sequelae](http://www.ncbi.nlm.nih.gov/pubmed/22689869), such as school failure, loss of digits, deafness, and intellectual impairment. GBS carriage by mother may also be causally related to stillbirth, spontaneous abortion and preterm birth ([26](#_ENREF_26)). Though there is very little data on neonatal GBS disease worldwide, studies in African countries have indicated [incidence as high as 1.21 per 1000 live births](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2742968/) ([27](#_ENREF_27)).

Some of these challenges are due to “vaccine hesitancy”. Vaccine-hesitant individuals may refuse some vaccines, but agree to others or delay vaccines and are influenced by a number of factors including issues of **confidence, complacency** and **convenience**/access ([1](#_ENREF_1)).

The Strategic Advisory Group of Experts (SAGE) on Immunization established a Working Group dealing with vaccine hesitancy in March 2012 ([28](#_ENREF_28)) The working group drafted a “Model of determinants of vaccine hesitancy” ([Fig. 1](http://www.sciencedirect.com/science/article/pii/S0264410X14001443#fig0005)) organized around three key domains: 1. Contextual influences – including historic, socio-cultural, environmental, health system/institutional, economic or political factors; 2. Individual and group influences – including influences arising from personal perception of the vaccine or influences of the social/peer environment; and, 3. Vaccine and vaccination-specific issues which are directly related to the characteristics of the vaccine or the vaccination process ([Fig. 1](http://www.sciencedirect.com/science/article/pii/S0264410X14001443#fig0005)). This model includes a broad selection of factors that have been identified as potential influencers of vaccine hesitancy drawn from the collective experience and insights of the SAGE WG members ([1](#_ENREF_1)). The model has been used in this literature review to categorise concerns surrounding vaccination during pregnancy.

To address some of these issues, communication strategies around the safety and effectiveness of the inactivated influenza and acellular pertussis vaccines in pregnancy have targeted pregnant women and HCW in some settings ([29](#_ENREF_29), [30](#_ENREF_30)). However, a Vaccine Hesitancy literature review conducted by The Vaccine Confidence Project in 2012 found only 42 out of 1164 articles focusing on vaccination during pregnancy and there have only been four systematic literature reviews conducted on factors associated with vaccination uptake during pregnancy. All of these reviews focused solely on the influenza vaccine. Two were published in 2010 ([31](#_ENREF_31), [32](#_ENREF_32)), one in 2011 ([33](#_ENREF_33)) and one in 2014 (with a search that was performed up to November 2013) ([34](#_ENREF_34)). The Bulifon et al. (2010) article identified influences on decision-making for influenza A/H1N1v vaccination among pregnant women ([31](#_ENREF_31)). The lack of information on influenza vaccination for pregnant women and confusing information relating to the risk of adverse foetal events following vaccination were reported. In France, these concerns led to the vaccine being discredited by the mass media and in the population before it became available. The Guthmann et al. (2010) article focused on reasons for the low uptake of the influenza vaccine in all groups in France, including pregnant women ([32](#_ENREF_32)). Bish et al. (2011) carried out a systematic literature review to examine the psychological and demographic factors associated with uptake of vaccination globally during the 2009 pandemic ([35](#_ENREF_35)) and Yuen et al (2014) carried out a literature review of factors influencing uptake of influenza vaccination during pregnancy in North America ([34](#_ENREF_34)).

With reference to the barriers to vaccination during pregnancy mentioned above and in the SAGE working Group Model of Determinants of Vaccine Hesitancy, the aim of this literature review was to analyse factors influencing uptake of vaccines in pregnancy, focusing on maternal and HCW concerns, trust and access issues.

**Methods**

Search Strategy

To analyse factors leading to uptake of all vaccines globally, a systematic review on vaccine hesitancy was carried out by The Vaccine Confidence Project in 2012 ([1](#_ENREF_1)):

*Systematic review on vaccine hesitancy search strategy*

A search strategy was developed in Medline and then adapted as required by differential indexing across several multidisciplinary mainstream and regional databases including: Medline, Embase Classic & Embase, PsychInfo, Cochrane, CINAHL Plus, Web of Science, IBSS, LILACS, AfricaWideInfo and IMEMR. The strategy included an extensive list of keywords (Table 1) and related MeSH/subject headings in an effort to capture the many dimensions and expressions of vaccine confidence, trust and hesitancy.

In order to analyse factors influencing uptake of vaccines in pregnancy, a further search was conducted, within the broader systematic review, using the terms 'Prenan\*' or 'Matern\*'. Forty-two articles were identified. The pregnancy-related articles were then screened to identify those which focused on maternal and HCW concerns, trust and access issues regarding vaccination. Thirty-five relevant articles were included which were then searched using the snowballing technique ([36](#_ENREF_36)) to identify relevant references cited in these articles. The snowballing technique was also used on articles recommended by peers as well as articles identified in a PubMed search as the original search conducted by the Vaccine Confidence Project commenced in 2012 and more relevant articles may have been published since then.

The PubMed search commenced on 19/02/2015 and ran until 22/04/2015 with the following terms: *(vaccin\* OR immuni\*) AND (pregnan\* OR maternal) AND (attitude OR awareness OR access OR predictors OR factors OR determinants OR refusal OR hesitancy OR acceptance)* (all dates were included).

Study Selection

Once retrieved, peer-reviewed articles were screened by title and abstract according to a set of inclusion and exclusion criteria (Table 2).

Data Analysis

Data was extracted from included articles and analysed in Excel.

**Results**

Thirty-eight out of 42 articles were included from the 2012 systematic literature review ([1](#_ENREF_1)). An additional 239 articles were found after using the snowballing technique with these articles (Figure 2). Fourteen articles were added from peer recommendations and 111 from the additional PubMed search alert. A total of 364 articles were screened by title and abstract. One hundred and eighty-three articles were excluded by title and abstract, two were not available by full text and one was not able to be translated (from Hungarian) due to copyright issues relating to the article*.* One hundred and seventy-eight articles were screened by full text and 61 were excluded by full text, resulting in 117 articles. There were a total of 155 articles including the relevant articles from the earlier vaccine hesitancy search (2012) ([1](#_ENREF_1)).These articles included 113 focusing on the influenza vaccine (A(H1N1), seasonal influenza or both), 16 on tetanus, seven on dTaP/ IPV, two on group b streptococcus (GBS) and 17 on any vaccine given in pregnancy.

Main findings

Almost all of the studies (113/155, 73%)focused on the influenza vaccine and of these, 73/113 (65%) were conducted in North America. *S*tudies focusing on the tetanus vaccine were focused mainly in Asia and Africa (8/16, 50% and 4/16, 25% respectively) (Figure 3).

There has been an increase in articles focusing on the determinants of influenza vaccination uptake in pregnancy since 2008, peaking at 26 articles in 2011. This has since declined to just seven in 2014 and three as of 21st April 2015. Most articles focusing on the tetanus vaccine (14/16, 88%) were published between 1970 and 2005 ([17](#_ENREF_17), [37-49](#_ENREF_37)). There were very few articles focusing on dTaP/ IPV with the most (4/7, 57%) published in 2014 and 2015 ([18](#_ENREF_18), [50](#_ENREF_50), [51](#_ENREF_51)) (Figure 4).

Sample sizes of pregnant women surveyed/interviewed in the included articles were between 17 and 6000.Nine articles reported on the number of women intending to vaccinate.

The main concerns cited in the included articles were regarding the safety of vaccines in pregnancy (64/155, 41%). Other frequently cited barriers were: concerns about the efficacy or the belief that the vaccine is not necessary (28/155, 18%); low knowledge about the vaccines and/or the diseases they prevent (among both pregnant women and HCW) (22/155, 14%); no recommendations from HCW (17/155, 10%); and access/availability issues (6/155, 4%). From the point of view of the HCW, barriers included inadequate reimbursement ([52](#_ENREF_52)) ([53](#_ENREF_53)) ([54](#_ENREF_54)) and training ([55](#_ENREF_55)) and increased workload ([56](#_ENREF_56)) (6/155, 4%). Other barriers were conflicting advice ([57-59](#_ENREF_57)), cost ([18](#_ENREF_18), [60](#_ENREF_60)) and religion ([61](#_ENREF_61)) (Figure 5).

When these varied concerns were mapped against the SAGE Working Group model of determinants of vaccine hesitancy (Figure 1), for all vaccines, more than half were grouped under ‘risks/benefits (perceived/heuristic)’ which includes safety concerns (83/155, 54%). The role of healthcare professionals was the second biggest category of issues (26/155, 17%) and included concerns such as no recommendation from the HCW. Inadequate knowledge of why, where, what and when vaccines are needed was also a barrier to vaccination (25/155, 16%). The main concerns regarding the influenza, dTaP/ IPV and group b streptococcus vaccine fell into the ‘risk/benefit (perceived/heuristic)’ category (mostly regarding the safety of the vaccine). The main concerns regarding the tetanus vaccine fell into the ‘knowledge of why/where/what/when vaccines are needed’ category (Figure 6).

One hundred and eleven out of 155 (72%) articles focused on attitudes towards vaccination in pregnancy among pregnant women/women who had recently given birth, 29/155 (19%) on attitudes of HCW and 15/155 (10%) on the attitudes of both. The main vaccine of focus was influenza both groups (i.e. pregnant women/mothers and HCWs). There have been no studies on HCW about attitudes towards tetanus vaccination provided during pregnancy. Articles focusing on attitudes of HCW were more likely to cite barriers regarding ‘knowledge of why/where/what/when vaccines are needed’ (7/29, 24%) than those focusing on pregnant women (15/111, 14%). (Note that these figures do not include the articles that focused on both pregnant women/new mothers and HCW).

These concerns were grouped into larger overarching categories according to the SAGE Working Group model of determinants (Fig.1). Most concerns fell into the ‘Individual/social group influences’ category (106/155, 68%), followed by ‘Vaccine & vaccine-specific issues’ (37/155, 24%) and ‘Contextual issues’ (11/155, 7%).

Only 46/155 (30%) articles mentioned ethnicity as a factor influencing vaccine uptake. Of these, the majority (38/155, 25%) focused on the influenza vaccine. Twenty-seven out of 46 (59%) articles reported lower rates of vaccination coverage among ethnic minorities ([45](#_ENREF_45), [57](#_ENREF_57), [61-84](#_ENREF_61)). Only 8/46 (17%) reported higher uptake rates among ethnic minorities and 11/46 (24%) reported no difference. One hundred and nine articles (70%) did not mention ethnicity as a factor related to vaccination uptake.

Five articles found that agreement/advice from the pregnant woman’s husband/partner significantly affected her likelihood to vaccinate ([47](#_ENREF_47), [48](#_ENREF_48), [85-87](#_ENREF_85)). In Canada, advice from a spouse was frequently considered important in the immunized group ([88](#_ENREF_88)). In the Ivory Coast, the agreement of the husband is considered necessary because he is the head of the family, the decision maker, and controls the money ([47](#_ENREF_47)). In Pakistan, unmarried females are not encouraged to get themselves vaccinated ([48](#_ENREF_48)). In Turkey, 37.9% of the study group stated that they made their decisions on their own, 10.5% said their vaccination decisions were made by their spouses and 51.5% said they decided with their spouses ([87](#_ENREF_87)) and in the USA, women cited their partner’s dissuasive role; often due to the latter’s lack of knowledge or own lower vaccine uptake ([85](#_ENREF_85)).

The recommendation from a HCW to receive vaccination during pregnancy was reported in most articles to increase vaccination uptake. In a study by Walker et al. (2011), it was found that women who were offered influenza vaccination by a HCW were more likely to be vaccinated (71%) than women who were not offered the vaccine (14%) and they were more likely to have positive attitudes about vaccine effectiveness and safety ([89](#_ENREF_89)).

**Discussion**

The aim of this literature review was to analyse factors contributing to uptake of vaccines in pregnancy, focusing on maternal and HCW concerns, trust and access issues.

The largest number of articles focused on the influenza vaccine and the primary focus on the influenza vaccine was in North America and most were published in 2011. This can be explained by the 2009 A (H1N1) pandemic. The number of articles focusing on the influenza vaccine has since declined and could be because it has now been six years since the last influenza pandemic*.*

The articles focusing on the tetanus vaccine were primarily in research on low-income countries and were mostly published between 1970 and 2005. ([90](#_ENREF_90)). There were very few articles focusing on dTaP/ IPV. This is surprising considering the relatively recent introduction of the vaccine during pregnancy in many countries.

The main concerns cited in the included articles were related to the safety of vaccines in pregnancy. While low knowledge about the vaccines, their efficacy, their availability and the diseases they prevent, were among the reasons for low vaccine uptake, as some studies reported, the role of the media regarding pregnant women’s knowledge about and decisions to vaccinate cannot be ignored ([86-88](#_ENREF_86), [91-93](#_ENREF_91)). Almost all articles mentioned that recommendations from a HCW to receive the vaccine had a large impact on vaccination uptake ([89](#_ENREF_89)).

When concerns were grouped into larger overarching categories of the SAGE model of determinants, most concerns fell into the ‘Individual/social group influences’ category (106/155, 68%). This demonstrates the extent that a pregnant woman’s social context and members of the local community, family and friends influence her decision to vaccinate. Five articles explicitly stated the husband/partner’s role in the decision to vaccinate.

Twenty-seven out of 46 (59%) articles reported lower vaccination uptake among ethnic minorities. One article ([81](#_ENREF_81)) on Ghana suggested that women from ethnic minorities are discriminated against due to their poor socio-economic position, languagebarriers that prevent them from understanding and communicating with HCW, access issues related to their geographical location and less health education.

Four literature reviews were found which focused on identifying factors associated with vaccination uptake in pregnancy. All four reviews focused on the influenza vaccine and the views of pregnant women. Two of the reviews ([31](#_ENREF_31), [32](#_ENREF_32)) focused on uptake in France.

Most of the literature focused on the views of pregnant women. Only 29/155 (19%) solely focused on views of the HCW. There is the need for more in-depth analysis on the barriers HCW cited to vaccination, including inadequate training, inadequate reimbursement and increased workload.

Although West Africa has the highest global burden of whooping cough thus far in 2015, with 500 cases reported in Liberia ([94](#_ENREF_94)), the dTaP/ IPV vaccine in pregnancy is not yet provided. The Middle East has had the highest burden of influenza ([95](#_ENREF_95)) but only one study was found within this literature review focusing on influenza vaccine uptake in the area (Turkey) ([87](#_ENREF_87)). As of March 2015, maternal and neonatal tetanus is still a public health problem in 23 countries, mostly in Africa as well as Afghanistan, Cambodia, Equatorial Guinea, Haiti, India, Indonesia, Iraq, Pakistan, Papua New Guinea, Philippines and Yemen. In the literature, tetanus vaccine uptake was reported in four African countries, as well as Bangladesh, India, Indonesia, Pakistan, Peru and Turkey([21](#_ENREF_21)).

**Conclusion**

This literature review has shown that both pregnant women and HCW cite safety concerns as a main barrier to obtaining/providing influenza and pertussis vaccines during pregnancy. However responses differed depending on geographical area. Regulatory agencies still don’t have a licensing pathway for many vaccines for pregnant women, manufacturers remain concerned about liability and providers perceive that pregnant women are unwilling to take vaccines ([26](#_ENREF_26)).

In low income countries, pregnant women were more likely to cite access issues as a barrier to vaccination.

The results show that barriers to vaccination in pregnancy are complex and vary depending on context and target population. There are wide gaps in knowledge regarding the attitudes of HCW to vaccination in pregnancy, which is significant considering the impact they have on a woman’s decision to vaccinate. It is also important to understand how ethnicity and gender dynamics in different cultural settings can influence a woman’s decision to vaccinate.

As the MDG era comes to an end, the development agenda beyond 2015 is widening to include important issues such as wellbeing and human capital and non-communicable diseases (NCDs). However, neither stillbirths nor neonatal deaths are mentioned in post-2015 documents ([96](#_ENREF_96)). Thus, previous momentum for new-borns risks being forgotten. The complex socio-political reasons for under-vaccination in certain communities globally, must be understood and acted upon if vaccines are to reach and protect pregnant women and their newborn from preventable disease.

**Authors’ contribution to the manuscript**: The manuscript has been read and approved by all named authors, who have worked collaboratively on the study design, search strategy, analysis and write-up. RW and CJ performed the literature search; and RW and PP screened the articles.

**Conflict of interest:** None

**Funding:** The LSHTM research group "The Vaccine Confidence Project" has received primary research funding from the Bill & Melinda Gates Foundation, with additional support from the Center for Strategic and International Studies, EU Innovative Medicines Initiative (IMI), GSK, National Institute for Health Research (UK), Novartis, and WHO. HL has done consulting on vaccine confidence with GSK and is a member of Merck Vaccine Strategic Advisory Board

**References**

1. Larson H, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: a systematic review of published literature, 2007-2012 Vaccine. 2014;32(19):2150-9.

2. Open Working Group proposal for Sustainable Development Goals: United Nations Department of Economic and Social Affairs; 2015 [20 May 2015]. Available from: https://sustainabledevelopment.un.org/sdgsproposal.

3. Gall SA, Myers J, M P. Maternal immunization with tetanus-diphtheria pertussis vaccine: effect on maternal and neonatal serum antibody levels Am J Obstet Gynecol. 2011 204:334.e1–e5.

4. Dlugacz Y, Fleischer A, Torroella Carney M, Copperman N, Ahmed I, Z R. 2009 H1N1 vaccination by pregnant women during the 2009-10 H1N1 influenza pandemic. Obstetrics. 2012 206 (4):339.e1–.e8.

5. England PH. Pertussis: the green book, chapter 24 [PDF]. England: Public Health England; 2015 [updated 28 April 201519 May 2015]. Available from: https://[www.gov.uk/government/uploads/system/uploads/attachment\_data/file/424448/Green\_Book\_Chapter\_24\_Pertussis\_v2\_0\_April\_2015.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/424448/Green_Book_Chapter_24_Pertussis_v2_0_April_2015.pdf).

6. McIntyre P, N W. Pertussis in early infancy: disease burden and preventive strategies. Current Opinion in Infectious Diseases. 2009;22:215–23.

7. Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn J, et al. Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. The Lancet. 2015;385(9966):430-40.

8. Lawn J, Blencowe H, Oza S, You D, Lee A, Waiswa P, et al. Every Newborn: progress, priorities, and potential beyond survival. The Lancet. 2014;384(9938):189–205.

9. UNICEF Data: Monitoring the Situation of Children and Women: Current Staus + Progress: UNICEF; 2015 [updated May 201520 May 2015]. Available from: <http://data.unicef.org/child-mortality/under-five>.

10. Impatient Optiminsts Bill & Melinda Gates Foundation; 2015 [20 May 2015]. Available from: <http://www.impatientoptimists.org/Posts/2015/03/Improving-Maternal-Immunization-Partners-Convene-to-Align-on-Way-Forward#.VVx6jPlVhBf>.

11. Mullooly JP, Barker WH, TF N. Risk of acute respiratory disease among pregnant women during influenza A epidemics. Public Health Rep. 1986;101:205-11.

12. Aronsson F, Lannebo C, Paucar M, Brask J, Kristensson K, H K. Persistence of viral RNA in the brain of offspring to mice infected with influenza A/WSN/33 virus during pregnancy. J Neurovirol. 2001:8353- 357.

13. Seasonal influenza vaccine uptake amongst GP patients in England: Provisional monthly data for 1 September 2014 to 30 November 2014: Public Health England; 2014 [cited 2014 1st December]. Available from: https://[www.gov.uk/government/uploads/system/uploads/attachment\_data/file/390281/2903322\_SeasonalFlu\_GP\_Nov14\_acc2.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/390281/2903322_SeasonalFlu_GP_Nov14_acc2.pdf). .

14. England PH. Pertussis Vaccination Programme for Pregnant Women: vaccine coverage estimates in England, September to December 2014 UK: Public Health England 2015 [27 April 2015]. Available from: https://[www.gov.uk/government/uploads/system/uploads/attachment\_data/file/408500/hpr0715\_prtsss-vc.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/408500/hpr0715_prtsss-vc.pdf).

15. Taksdal SE, Mak DB, Joyce S, Tomlin S, Carcione D, Armstrong PK, et al. Predictors of uptake of influenza vaccination: A survey of pregnant women in Western Australia. Aust Fam Physician. 2013 42 (8):582586.

16. Yuen CYS, Fong DYT, Lee ILY, Chu S, Siu ES, M T. Prevalence and predictors of maternal seasonal influenza vaccination in Hong Kong Vaccine 2013 31 5281– 8.

17. Dickin KL, Binchan RK, Purdue SE, Obinya EA. Perceptions of neonatal tetanus and immunization during pregnancy: A report of focus group discussions in Kaduna, Nigeria. International Quarterly of Community Health Education. 1991;11(4):371-83.

18. Housey M, Zhang F, Miller C, Lyon-Callo S, McFadden J, Garcia E, et al. Vaccination with Tetanus, Diphtheria, and Acellular Pertussis Vaccine of Pregnant Women Enrolled in Medicaid — Michigan, 2011–2013. Morbidity and Mortality Weekly Report (MMWR) 2014;63(38 ):839-42.

19. Gall S, Poland G. A maternal immunization program (MIP): Developing a schedule and platform for routine immunization during pregnancy. Vaccine. 2011;29(51):9411-3.

20. Wiley KE, Massey PD, Cooper SC, Wood N, Quinn HE, J. L. Pregnant women's intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine while pregnant: a cross sectional survey. P Vaccine. 2013;31 (37):3972-8.

21. Maternal and Neonatal Tetanus (MNT) elimination: WHO; 2015 [30 April 2015]. Available from: <http://www.who.int/immunization/diseases/MNTE_initiative/en/index1.html>.

22. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus (Structured abstract). International journal of epidemiology. 2010;39(Supplement 1):i102-i9.

23. Blencowe H, Cousens S, Mullany L, Lee A, Kerber K, Wall S, et al. Clean birth and postnatal care practices to reduce neonatal deaths from sepsis and tetanus: a systematic review and Delphi estimation of mortality effect. BMC Public Health. 2011;11 (suppl 3):11.

24. Roper M, Vandelaer J, Gasse F. Maternal and neonatal tetanus. The Lancet. 2007;370(9603):1947–59.

25. Puopolo K. Current Status of Vaccine Development for Group B Streptococcus. NeoReviews. 2014;15 (10):e430-e8.

26. Youngdahl K. NFID Conference: Challenges of Maternal Immunization: This History of Vaccines Blog; 2013 [19 May 2015]. Available from: <http://www.historyofvaccines.org/content/blog/nfid-conference-challenges-maternal-immunization>.

27. Johri A, Paoletti L, Glaser P, Dua M, Sharma P, Grandi G, et al. Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol. 2006;4(12):932–42.

28. SAGE working group dealing with vaccine hesitancy (March 2012 to November 2014): WHO; 2012 [19 May 2015]. Available from: <http://www.who.int/immunization/sage/sage_wg_vaccine_hesitancy_apr12/en/>.

29. NHS. The Flu Vaccination: Winter 2014/15: Who should have it and why UK: NHS; 2014 [27 April 2015]. Available from: https://[www.gov.uk/government/uploads/system/uploads/attachment\_data/file/368079/PHE\_8879\_Flu\_2014\_A5\_General\_leaflet\_14\_.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/368079/PHE_8879_Flu_2014_A5_General_leaflet_14_.pdf).

30. NHS. Whooping cough and pregnancy the safest way to protect yourself and your baby: What you need to know and do to help protect your baby UK: NHS; 2014 [27 April 2015]. Available from: https://[www.gov.uk/government/uploads/system/uploads/attachment\_data/file/323517/WhoopingCough\_DL\_flyer\_2014\_04\_.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/323517/WhoopingCough_DL_flyer_2014_04_.pdf).

31. Bulifon S, Tsatsaris V, Goffinet F, Mignon A, Batteux F, Delfraissy JF, et al. Pandémie grippale A/H1N1v, grossesse et vaccination. Médecine et Maladies Infectieuses. 2010 40(12):696–702.

32. Guthmann J, Bone A, J N, D L-B. Insuffisance de couverture vaccinale grippale A(H1N1)2009 en population générale et dans les groupes à risque durant la pandémie 2009-2010 en France. BEHWeb. 2010;3:09-16.

33. Bish A, Yardley L, Nicoll A, S. M. Factors associated with uptake of vaccination against pandemic influenza: a systematic review. Vaccine 2011 29 (38):6472-84.

34. Yuen CY, M T. Determinants of uptake of influenza vaccination among pregnant women - a systematic review Vaccine. 2014;32(36):4602-13.

35. Bish A, Yardley L, Nicoll A, Michie S. Factors associated with uptake of vaccination against pandemic influenza: A systematic review. Vaccine. 2011;29(38):6472-84.

36. Jalali S, C W, editors. Systematic literature studies: Database searches vs. backward snowballing. ESEM '12 Proceedings of the ACM-IEEE international symposium on Empirical software engineering and measurement:; 2012.

37. Rahman M, Chen LC, Chakraborty J. Use of tetanus toxoid for the prevention of neonatal tetanus. II. Immunization acceptance among pregnant women in rural Bangladesh. Bulletin of the World Health Organization. 1982;60(2):269-77.

38. Buekens P, Tsui A, Kotelchuck M, Degraft-Johnson J. Tetanus immunization and prenatal care in developing countries. Int J Gynaecol Obstet. 1995;48(1):91-4.

39. Galazka A, Gasse F. The present status of tetanus and tetanus vaccination. Curr Top Microbiol Immunol. 1995;195:31-53.

40. Jamil K, Bhuiya A, Streatfield K, Chakrabarty N. The immunization programme in Bangladesh: impressive gains in coverage, but gaps remain. Health Policy & Planning. 1999;14(1):49-58.

41. Gupta S, Keyl P. Effectiveness of prenatal tetanus toxoid immunization against neonatal tetanus in a rural area in India. Pediatr Infect Dis J. 1998;17(4):316-21.

42. Madico G, Salazar G, McDonald J, Checkley W, Calderón M, Verastegui M, et al. Rates of tetanus protection and transplacental tetanus antibody transfer in pregnant women from different socioeconomic groups in Peru. Clin Diagn Lab Immunol. 1996;3(6):753-5.

43. Roosihermiatie B, Nishiyama M, Nakae K. Factors associated with TT (tetanus toxoid) immunization among pregnant women, in Saparua, Maluku, Indonesia. Southeast Asian J Trop Med Public Health. 2000;31(1):91-5.

44. Maral I, Baykan Z, Aksakal F, Kayikcioglu F, Bumin M. Tetanus immunization in pregnant women: evaluation of maternal tetanus vaccination status and factors affecting rate of vaccination coverage. Public Health. 2001;115(5):359-64.

45. Navaneetham K, Dharmalingam A. Utilization of maternal health care services in Southern India. Soc Sci Med. 2002;55(10):1849-69.

46. Deming M, Roungou J, Kristiansen M, Heron I, Yango A, Guenengafo A, et al. Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus. Bull World Health Organ. 2002;80(9):696–703.

47. Ymba A, Perrey C. Acceptability of tetanus toxoid vaccine by pregnant women in two health centres in Abidjan (Ivory Coast). Vaccine. 2003;21(24):3497-500.

48. Afridi NK, Hatcher J, Mahmud S, Nanan D. Coverage and factors associated with tetanus toxoid vaccination status among females of reproductive age in Peshawar. Journal of the College of Physicians and Surgeons Pakistan. 2005;15(7):391-5.

49. Thind A. Determinants of tetanus toxoid immunization in pregnancy in rural Bihar. Tropical doctor. 2005;35(2):75-7.

50. Varan A, Esteves-Jaramillo A, Richardson V, Esparza-Aguilar M, Cervantes-Powell P, SB O. Intention to accept Bordetella pertussis booster vaccine during pregnancy in Mexico City. Vaccine. 2014;32(7):785-92.

51. Bonville C, Cibula D, Domachowske J, Suryadevara M. Vaccine attitudes and practices among obstetric providers in New York State following the recommendation for pertussis vaccination during pregnancy. Hum Vaccin Immunother. 2015;[Epub ahead of print].

52. Kissin DM, Power ML, Kahn EB, Williams JL, Jamieson DJ, MacFarlane K, et al. Attitudes and practices of obstetrician-gynecologists regarding influenza vaccination in pregnancy. Obstetrics & Gynecology. 2011;118(5):1074-80.

53. Leddy MA, Anderson BL, Power ML, Gall S, Gonik B, Schulkin J. Changes in and current status of obstetrician-gynecologists' knowledge, attitudes, and practice regarding immunization. Obstetrical & gynecological survey. 2009;64(12):823-9.

54. Power ML, Leddy MA, Anderson BL, Gall SA, Gonik B, Schulkin J. Obstetrician-gynecologists' practices and perceived knowledge regarding immunization. American Journal of Preventive Medicine. 2009;37(3):231-4.

55. Beigi RH, Switzer GE, Meyn LA. Acceptance of a pandemic avian influenza vaccine in pregnancy. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2009;54(6):341-6.

56. Ishola DJ, Permalloo N, Cordery R, Anderson S. Midwives' influenza vaccine uptake and their views on vaccination of pregnant women. J Public Health (Oxf). 2013;35(4):570-7.

57. Cassady D, Castaneda X, Ruelas MR, Vostrejs MM, Andrews T, Osorio L. Pandemics and Vaccines: Perceptions, Reactions, and Lessons Learned from Hard-to-Reach Latinos and the H1N1 Campaign. Journal of Health Care for the Poor and Underserved. 2012;23:1106-22.

58. Hanquet G, Van Damme P, Brasseur D, De Cuyper X, Gregor S, Holmberg M, et al. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine. 2011;29(3):370-7.

59. Mersereau PW, Layton CM, Smith LR, Kendrick JS, Mitchell EW, Amoozegar JB, et al. Prenatal care providers and influenza prevention and treatment: lessons from the field. Maternal & Child Health Journal. 2012;16(2):479-85.

60. Link-Gelles R, Chamberlain A, Schulkin J, Ault K, Whitney E, Seib K, et al. Missed Opportunities: A National Survey of Obstetricians About Attitudes on Maternal and Infant Immunization. Maternal & Child Health Journal. 2012;16(9):1743-7.

61. Gyimah SO, Takyi BK, Addai I. Challenges to the reproductive-health needs of African women: on religion and maternal health utilization in Ghana. Social science & medicine. 2006;62(12):2930-44.

62. Ahluwalia, Jamieson D, D'Angelo D, Singleton J, Santibanez M, G Euler G, et al. Seasonal Influenza and 2009 H1N1 Influenza Vaccination Coverage Among Pregnant Women --- 10 States, 2009--10 Influenza Season. CDC Morbidity and Mortality Weekly Report (MMWR). 2010;59(47):1541-5.

63. Ball S, Donahue S, Izrael D, Walker D, Martonik R, DiSogra C, et al. Influenza Vaccination Coverage Among Pregnant Women — United States, 2012–13 Influenza Season. CDC Morbidity and Mortality Weekly Report (MMWR). 2013; 62(38):787-92.

64. Blondel B, Mahjoub N, Drewniak N, Launay O, Goffinet F. Failure of the vaccination campaign against A(H1N1) influenza in pregnant women in France: results from a national survey. Vaccine. 2012;30(38):5661-5.

65. Bödeker B, Walter D, Reiter S, Wichmann O. Cross-sectional study on factors associated with influenza vaccine uptake and pertussis vaccination status among pregnant women in Germany. Vaccine 2014 32(33):4131-9.

66. Ding H, Santibanez TA, Jamieson DJ, Weinbaum CM, Euler GL, Grohskopf LA, et al. Influenza vaccination coverage among pregnant womenNational 2009 H1N1 Flu Survey (NHFS). American Journal of Obstetrics and Gynecology. 2011;204(6 SUPPL):S96-S106.

67. Drees M, Tambourelli B, Denstman A, Zhang W, Zent R, McGraw P, et al. Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-2011 influenza season. Vaccine. 2013;31(2):362-6.

68. Eppes C, Wu A, You W, Cameron KA, Garcia P, Grobman W. Barriers to influenza vaccination among pregnant women. Vaccine. 2013;31(27):2874-8.

69. Freund R, Le Ray C, Charlier C, Avenell C, Truster V, Treluyer JM, et al. Determinants of non-vaccination against pandemic 2009 H1N1 influenza in pregnant women: A prospective cohort study. PLoS ONE. 2011;6 (6) , 2011:ate of Pubaton: 2011.

70. Gorman JR, Brewer NT, Wang JB, Chambers CD. Theory-based predictors of influenza vaccination among pregnant women.  . Vaccine. 2012;31(1):213-8.

71. Lu P, Bridges CB, Euler GL, Singleton JA. Influenza vaccination of recommended adult populations, U.S., 1989-2005. Vaccine. 2008;26(14):1786-93.

72. Panda B, Stiller R, Panda A. Influenza vaccination during pregnancy and factors for lacking compliance with current CDC guidelines. Journal of Maternal-Fetal and Neonatal Medicine. 2010;24(3):402-6.

73. Vitek WS, Akers A, Meyn LA, Switzer GE, Lee BY, Beigi RH. Vaccine eligibility and acceptance among ambulatory obstetric and gynecologic patients. Vaccine. 2011;29(11):2024-8.

74. Chamberlain A, Seib K, Ault K, Orenstein W, Frew P, Malik F, et al. Factors Associated with Intention to Receive Influenza and Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines during Pregnancy: A Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety. PLoS Current Outbreaks. 2015.

75. Drees M, Johnson O, Wong E, Stewart A, Ferisin S, Silverman PR, et al. Acceptance of 2009 H1N1 influenza vaccine among pregnant women in Delaware. American Journal of Perinatology. 2012;29(4):289-94.

76. Fisher BM, Scott J, Hart J, Winn VD, Gibbs RS, Lynch AM. Behaviors and perceptions regarding seasonal and H1N1 influenza vaccination during pregnancy. American Journal of Obstetrics and Gynecology. 2011;204(6 SUPPL):S107-S11.

77. Fridman D, Steinberg E, Azhar E, Weedon J, Wilson TE, Minkoff H. Predictors of H1N1 vaccination in pregnancy. American Journal of Obstetrics and Gynecology. 2011;204(6 SUPPL):S124-S7.

78. Goldfarb I, Panda B, Wylie B, Riley L. Uptake of influenza vaccine in pregnant women during the 2009 H1N1 influenza pandemic. American Journal of Obstetrics & Gynecology. 2011;204(6):S112-5.

79. Kharbanda EO, Vargas CY, Castano PM, Lara M, Andres R, Stockwell MS. Exploring pregnant women's views on influenza vaccination and educational text messages. Preventive Medicine: An International Journal Devoted to Practice and Theory. 2011;52(1):75-7.

80. Steelfisher GK, Blendon RJ, Bekheit MM, Mitchell EW, Williams J, Lubell K, et al. Novel pandemic A (H1N1) influenza vaccination among pregnant women: motivators and barriers. American Journal of Obstetrics & Gynecology. 2011;204(6):S116-23.

81. Ganle J, Parker M, Fitzpatrick R, Otupiri E. Inequities in accessibility to and utilisation of maternal health services in Ghana after user-fee exemption: a descriptive study. Int J Equity Health. 2014;13:89.

82. Wong C, Thomas N, Clarke M, Boros C, Tuckerman J, Marshall H. Maternal uptake of pertussis cocooning strategy and other pregnancy related recommended immunizations. Human Vaccines & Immunotherapeutics. 2015;[epub ahead of print].

83. Henninger M, Irving S, Thompson M, Avalos L, Ball S, Shifflett P, et al. Factors Associated with Seasonal Influenza Vaccination in Pregnant Women. Journal of Womens Health. 2015;24(5):[Epub ahead of print].

84. Laenen J, Roelants M, Devlieger R, Vandermeulen C. Influenza and pertussis vaccination coverage in pregnant women. Vaccine. 2015;33(18):2125-31.

85. Meharry P, Colson E, Grizas A, Stiller R, Vázquez M. Reasons Why Women Accept or Reject the Trivalent Inactivated Influenza Vaccine (TIV) During Pregnancy. Maternal & Child Health Journal. 2013;17(1):156-64.

86. Fabry P, Gagneur A, Pasquier JC. Understanding pregnant womens intentions to have the A/H1N1 vaccine. American Journal of Obstetrics and Gynecology. 2011;204:S247-S.

87. Ozer A, Arikan DC, Kirecci E, Ekerbicer HC. Status of pandemic influenza vaccination and factors affecting it in pregnant women in Kahramanmaras, an eastern Mediterranean city of Turkey. PloS one. 2010;5(12):e14177.

88. Fabry P, Gagneur A, Pasquier JC. Determinants of A (H1N1) vaccination: Cross-sectional study in a population of pregnant women in Quebec. Vaccine. 2011;29(9):1824-9.

89. Walker D, Ball S, Black R, Izrael D, Ding H, Euler G, et al. Influenza Vaccination Coverage Among Pregnant Women-United States, 2010--11 Influenza Season. CDC Morbidity and Mortality Weekly Report (MMWR). 2011;60(32):1078-82.

90. Maternal and Neonatal Tetanus (MNT) elimination: WHO; 2015 [20 May 2015]. Available from: <http://www.who.int/immunization/diseases/MNTE_initiative/en/>.

91. Luteijn J, Dolk H, Marnoch G. Differences in pandemic influenza vaccination policies for pregnant women in Europe. BMC Public Health. 2011;11(819).

92. Mirdamadi K, Einarson A. H1N1 and influenza viruses: why pregnant women might be hesitant to be vaccinated. Canadian Family Physician. 2011;57(9):1003-4.

93. Sakaguchi S, Weitzner B, Carey N, Bozzo P, Mirdamadi K, Samuel N, et al. Pregnant women's perception of risk with use of the H1N1 vaccine. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2011;33(5):460-7.

94. Vaccine-Preventable Outbreaks: Council on Foreign Relations; 2015 [30 April 2015]. Available from: <http://www.cfr.org/interactives/GH_Vaccine_Map/#map>.

95. Influenza update: 20 April 2015 - Update number 235, based on data up to 05 April 2015: WHO; 2015 [cited 30 April 2015]. Available from: <http://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/>.

96. The Report of the High-Level Panel of Eminent Persons on the Post-2015 Development. A new global partnership: eradicate poverty and transform economies through sustainable development New York: UN; 2013 [20 May 2015]. Available from: <http://www.un.org/sg/management/pdf/HLP_P2015_Report.pdf>.